Cite
Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer's disease mouse model by regulating the expression of APP secretases.
MLA
Zhang, Miaomiao, et al. “Histone Deacetylase Inhibitors VPA and WT161 Ameliorate the Pathological Features and Cognitive Impairments of the APP/PS1 Alzheimer’s Disease Mouse Model by Regulating the Expression of APP Secretases.” Alzheimer’s Research & Therapy, vol. 16, no. 1, Jan. 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1186/s13195-024-01384-0.
APA
Zhang, M., Wang, W., Ye, Q., Fu, Y., Li, X., Yang, K., Gao, F., Zhou, A., Wei, Y., Tian, S., Li, S., Wei, F., Shi, W., & Li, W.-D. (2024). Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases. Alzheimer’s Research & Therapy, 16(1), 1–20. https://doi.org/10.1186/s13195-024-01384-0
Chicago
Zhang, Miaomiao, Wanyao Wang, Qun Ye, Yun Fu, Xuemin Li, Ke Yang, Fan Gao, et al. 2024. “Histone Deacetylase Inhibitors VPA and WT161 Ameliorate the Pathological Features and Cognitive Impairments of the APP/PS1 Alzheimer’s Disease Mouse Model by Regulating the Expression of APP Secretases.” Alzheimer’s Research & Therapy 16 (1): 1–20. doi:10.1186/s13195-024-01384-0.